Adaptamtx

San Sebastián, ES · 1 known investors

Adaptam Therapeutics develops antibody-based cancer immunotherapies, including antibody-drug conjugates and bispecific antibodies, that target the immunosuppressive myeloid tumor microenvironment via novel targets such as glycan-binding proteins and Siglecs. A spin-off from CIC bioGUNE, the company serves oncology patients and is developing first-in-class therapies for multiple cancer indications.